Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients

Addiction(2024)10.1111/add.16630Source: DataRank Database

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients is a research paper published in Addiction (2024). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 4.59)OA: bronzeTopics (80)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Edward V. Nunes ORCID,Mark Olfson,Matisyahu Shulman ORCID,Noa Krawczyk ORCID,Elizabeth A. Stuart ORCID

Live enrichment

PubMed:39099417 PMC:PMC11479822 OpenAlex:https://openalex.org/W4401342330

National Institute on Drug Abuse

Grant: 5R01DA056407

NIDA NIH HHS

Grant: R01 DA056407

National Institutes of Health

Grant: 1R01DA056407-01

Design and analysis advances to improve generalizability of clinical trials for treating opioid use disorder

FWCI

4.59

Citation Percentile

1.0%

Citation Trend

2025

2026

bronzeLicense: CC BY NC ND

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.16630

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.16630

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/add.16630

journalhttps://doi.org/10.1111/add.16630

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39099417

Fields of Study

Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk03 medical and health sciences0305 other medical scienceHumansOpioid-Related DisordersNaltrexoneAdultFemaleDelayed-Action PreparationsBuprenorphineMaleUnited StatesMedicaidNarcotic AntagonistsYoung AdultMiddle AgedAdolescentAdministration, SublingualOpiate Substitution TreatmentCaliforniaNew JerseyCohort StudiesTreatment OutcomeDrug Overdose

MeSH Terms

Administration, SublingualAdolescentAdultBuprenorphineCaliforniaDelayed-Action PreparationsFemaleHumansMaleMedicaidMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersNew JerseyUnited StatesCohort StudiesTreatment OutcomeYoung AdultOpiate Substitution TreatmentDrug Overdose

Keywords

NaltrexoneBuprenorphineOpioid use disorderMedicineMedicaidOpioidNarcotic antagonistsPsychiatryPharmacologyAnesthesia(+)-NaloxoneInternal medicineOverdoseTreatment RetentionSublingual BuprenorphineExtended‐release NaltrexoneAdultMaleAdolescentNew JerseyAdministration, SublingualMiddle AgedOpioid-Related DisordersArticleUnited StatesCaliforniaCohort StudiesYoung AdultTreatment OutcomeDelayed-Action PreparationsOpiate Substitution TreatmentHumansFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being